Clinical Trials Logo

Neoplasm, Residual clinical trials

View clinical trials related to Neoplasm, Residual.

Filter by:

NCT ID: NCT03703427 Not yet recruiting - Clinical trials for Pathologic Residual Cancer Cells

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Start date: November 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the efficacy and safety of capecitabine versus vinorelbine as a postoperative adjuvant chemotherapy, for high risk breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.

NCT ID: NCT03699384 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Start date: October 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I / II study. The purposes of this study are to: 1) find out what effects, good and/or bad, the combination of the experimental drug avelumab and the drug azacitidine has on people with AML and MRD, and 2) test if the two drugs, avelumab and azacitidine, are effective in getting rid of AML MRD when the drugs are given together in combination.

NCT ID: NCT03697655 Not yet recruiting - Multiple Myeloma Clinical Trials

Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

PREDATOR
Start date: October 2018
Phase: Phase 2
Study type: Interventional

PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).

NCT ID: NCT03686215 Not yet recruiting - Breast Cancer Clinical Trials

Pivotal Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Start date: December 2018
Phase: Phase 3
Study type: Interventional

This is a multi-center, single-arm pivotal study to demonstrate the safety and efficacy of the LUM Imaging System (LUM015 imaging agent in conjunction with the LUM Imaging Device and decision software), in identifying residual cancer in the lumpectomy bed of female breast cancer patients undergoing breast in order to assist surgeons in reducing the rates of positive margins. In this study, patients will be injected with LUM015 prior to surgery. The study physician should perform their standard of care lumpectomy, which may include the removal of shaves. Therapeutic (Lumicell guided) shaves will be removed based on the recommendation of the LUM Imaging System after the standard of care lumpectomy. Patients will be followed until their first standard of care post-operative follow-up visit.

NCT ID: NCT03684863 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Start date: October 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for HER-2 positive breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.

NCT ID: NCT03665480 Recruiting - Clinical trials for Acute Myeloid Leukemia

The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML

Start date: September 4, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Granulocyte-colony stimulating factor (G-CSF) is konwn to have no significant effect on leukemia stem cells and has been widely used in the patients with agranulocytosis after chemotherapy. Minimal residual disease (MRD), an index for early treatment response, plays an important role in prognostic prediction. Numbers of data have shown MRD at day 14 after induction therapy significantly predicts prognosis. However, the retrospetive data from the investigators showed that patients with G-CSF treatment after induction had higher MRD at day 14 but not significantly different at day 28, suggesting that G-CSF might work on the differenciation of hemapoetic stem cells and increase MRD levels at day 14. In this multicenter prospective randomized controlled study, the effect of G-CSF on MRD after induction therapy in newly diagnosed acute myeloid leukemia (AML) is evaluated.

NCT ID: NCT03662087 Recruiting - Clinical trials for Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Start date: October 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse is the most common problem affecting long-term survivors of allo-HSCT. Therapy options for relapse include stopping immune suppression, re-induction of chemotherapy, donor lymphocyte infusion (DLI) or combination therapy. In this prospective randomized controlled study, the safety and efficacy of hypomethylating agents (HMA) + DLI and DLI preemptive therapy based on minimal residual disease in acute leukemia undergoing allo-HSCT are evaluated.

NCT ID: NCT03624530 Recruiting - Clinical trials for Minimal Residual Disease

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Start date: August 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Relapse remains a major cause of treatment failure even after allo-HSCT. The prevention of relapse is essential for improving the outcome of Ph+ ALL. Our previous clinical trial (ID: NCT01883219) demonstrated that pre-emptive tyrosine kinase inhibitor (TKIs) administration based on minimal residual disease (MRD) and BCR-ABL mutation after allo-HSCT might reduce the incidence of relapses and improve survival for patients with Ph+ ALL. Moreover, our result suggested that Ph+ ALL with MRD positive pre-transplants had the higher rate of molecular biology relapse. In this study, we will evaluate the safety and efficacy of prophylactic TKI therapy post-transplants on Ph+ ALL undergoing allo-HSCT with MRD positive pre-transplants.

NCT ID: NCT03614689 Recruiting - Ovarian Cancer Clinical Trials

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

Start date: November 25, 2017
Phase:
Study type: Observational

To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.

NCT ID: NCT03602898 Not yet recruiting - Clinical trials for Myelodysplastic Syndrome

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate for GVHD Prophylaxis in Myeloablative Unrelated Donor Transplantation

Start date: November 17, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well 3 different drug combinations prevent graft versus host disease (GVHD) after donor stem cell transplant. Calcineurin inhibitors, such as cyclosporine and tacrolimus, may stop the activity of donor cells that can cause GVHD. Chemotherapy drugs, such as cyclophosphamide and methotrexate, may also stop the donor cells that can lead to GVHD while not affecting the cancer-fighting donor cells. Immunosuppressive therapy, such as anti-thymocyte globulin (ATG), is used to decrease the body's immune response and reduces the risk of GVHD. It is not yet known which combination of drugs: 1) ATG, methotrexate, and calcineurin inhibitor 2) cyclophosphamide and calcineurin inhibitor, or 3) methotrexate and calcineurin inhibitor may work best to prevent graft versus host disease and result in best overall outcome after donor stem cell transplant.